Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmaceutical Medicine|April 28, 2023
Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and BeyondLisa Gieber, Vincent Muturi-Kioi, Shelly Malhotra, et al.
BMC Infectious Diseases|September 11, 2019
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerationsEmily A Kendall, Shelly Malhotra, Sarah Cook-Scalise, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov ModelEmily A Kendall, Shelly Malhotra, Sarah Cook-Scalise, et al.
Plos One|July 30, 2015
Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods StudyNatalie Lorent, Kimcheng Choun, Shelly Malhotra, et al.
Pharmacoeconomics|March 29, 2023
Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental ModelsRebecca Giddings, Pitchaya Indravudh, Graham F Medley, et al.
PLOS Global Public Health|July 1, 2024
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countriesShelly Malhotra, Anne-Isabelle Cameron, Dzintars Gotham, et al.
Pharmacoeconomics|December 18, 2022
Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature ReviewFiammetta M Bozzani, Fern Terris-Prestholt, Matthew Quaife, et al.
JMIR Research Protocols|February 7, 2024
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative StudyJoyeeta Mukherjee, Shruta Rawat, Saif Ul Hadi, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
Pharmacoeconomics|March 11, 2023
Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way ForwardSergio Torres-Rueda, Fern Terris-Prestholt, Mitzy Gafos, et al.
Pageof 2